Fresenius SE & Co KGAA O.N. (0OO9)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 45.08 |
|---|---|
| 52-week range | 35.13 – 51.44 |
| Return, 1 month / 3 months | −0.1% / +3.6% |
| Return, 1 year / 3 years | −1.6% / +89.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 55 |
| Volatility (1 year) | 25.8% |
| Worst drawdown (1 year) | -30.2% |
| Average daily value traded | 12.59M EUR |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fresenius is a German healthcare group based in Bad Homburg that provides products and services for dialysis, infusion therapy and hospital care. Through its dialysis business it operates treatment centres and makes equipment and disposables for kidney patients. Its medicines and nutrition arm supplies hospitals with intravenous drugs, infusion solutions and clinical nutrition, while its hospital division runs private clinics. Customers are mainly hospitals, clinics and dialysis patients across Europe and other regions.
The shares are listed on the London Exchange in UK under the code 0OO9, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fresenius SE & Co KGAA O.N. (0OO9) trades on the London Exchange in UK. It last closed at EUR 45.08 on 20 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,398 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.6% and over the last three months it rose 3.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.8% | ||
| From 52-week high | -11.3% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.6% | ||
| 6-month return | 5.9% | ||
| 12-month return, skipping the last month | -1.5% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 25.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.2% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 12.59M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 37 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | −0.1% |
| 3 months | +3.6% |
| 6 months | +5.9% |
| 1 year | −1.6% |
| 3 years | +89.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 45.12 / 43.83 |
|---|---|
| Golden / death cross (60 days) | Golden, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.31 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 1.0500 |
| 23 May 2025 | EUR 1.0000 |
| 18 May 2023 | EUR 0.9200 |
| 16 May 2022 | EUR 0.6600 |
| 24 May 2021 | EUR 0.8800 |
| 31 Aug 2020 | EUR 0.8400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.